Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
Save for later
Funded Studies
Donate Now
Funding Save for later

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2500${count})
  • Clinical Intervention Awards, 2012
    Phase I Study of AAV2-hAADC Administered by MRI-guided Real-time Convective Infusion

    Objective/Rationale:
    The purpose of this study is to provide safety data related to enhancements in the clinical delivery procedure for administering Adeno-Associated Virus Encoding Human Aromatic L...
    Researchers:

    Chadwick Wilson Christine, MD | Krystof Bankiewicz, MD, PhD | Paul Larson, MD | John G. Nutt, MD

    Details
  • Repositioning Drugs for PD, 2012
    Amitriptyline as a Dopamine Neuroprotective Therapy

    Objective/Rationale:
    The project proposes to repurpose the tricyclic antidepressant medication, amitriptyline (AMI), as a disease-modifying therapy for Parkinson’s disease (PD). AMI is an FDA-approved...
    Researchers:

    Timothy J. Collier, PhD

    Details
  • Neurotrophic Factors Challenge, 2012
    Validation of IGF-1 as a Neuroprotective Agent in Pre-clinical Models of Parkinson’s Disease
    Objective/Rationale: IGF-1-mediated intracellular signaling pathways engage a wide range of potential survival mechanisms, the PI3K/Akt pathway and the ER stress response in particular, and it has...
    Researchers:

    Anders Björklund, MD, PhD | Mickael Decressac, PhD

    Details
  • Clinical Intervention Awards, 2011
    First-in-human Trial to Assess the Safety and Tolerability of PD01, the First Alpha-synuclein-based AFFITOPE® Parkinson's Vaccine

    Objective/Rationale:
    Parkinson’s disease (PD) is characterized by the presence of protein aggregates called Lewy bodies, with a major component of the protein alpha-synuclein. This fact and...
    Researchers:

    Achim Schneeberger, MD | Markus Mandler, PhD

    Details
  • Rapid Response Innovation Awards, 2011
    Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD

    Objective/Rationale:
    Many genetic disorders are caused by the loss of a functional protein which protects cells from disease. These disorders are difficult to treat with drugs because most drugs...
    Researchers:

    Kevan M. Shokat, PhD

    Details
  • Target Validation, 2011
    Targeting of Alpha-synuclein and SNARE Complex Dysfunction to Restore Synaptic Dopamine Release in a Model of Parkinson Disease Pathology

    Objective/Rationale:
    Research data has recently indicated that pathology in Parkinson’s disease (PD) starts at the synapse, the part of the neurons where the release of dopamine occurs, dysfunction of...
    Researchers:

    Maria Grazia Spillantini, PhD | Oleg Anichtchik, MD, PhD

    Details
Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.